Table 1.
Clinical characteristics of Fusarium sp keratitis
|
Fusarium sp total (N=50) |
F. solani (N=38) |
F. non-solani (N=12) |
p-value | ||
|---|---|---|---|---|---|
| Gender | Male | 22 (44%) | 17 (45%) | 5 (42%) | 1.00* |
| Female | 28 (56%) | 21 (55%) | 7 (58%) | ||
| Age (mean(SD)) | 39 (19) | 39 (20) | 40 (18) | 0.97** | |
| CL wear | 33 (66%) | 24 (63%) | 9 (75%) | 0.51* | |
| Trauma | 9 (18%) | 7 (18%) | 2 (17%) | 1.00* | |
| Infiltrate’s location | 1.00* | ||||
| Central 6mm | 36 (72%) | 27 (71%) | 9 (75%) | ||
| Peripheral | 14 (28%) | 11 (29%) | 3 (25%) | ||
| Smear (+) results | |||||
| Cornea | 14/34 (41%) | 11/29 (38%) | 3/5 (60%) | 0.63* | |
| CL smear | 1/12 (8%) | 1/5 (20%) | 0/7 (0%) | 0.42* | |
| A/C | 0/3 (0%) | 0/3 (0%) | 0 | N/A | |
| Vitreous | 0/1 (0%) | 0/1 (0%) | 0 | N/A | |
| Total | 15/50 (30%) | 12/38 (32%) | 3/12 (25%) | 1.00* | |
| Time to (+) culture† (days) | 3.6 (2.9) (Range: 2–12) |
3.5 (3.1) (range: 2–12) |
3.8 (2.1) (range: 2–11) |
0.8** | |
| Treatment delay (days) | 9.7 (7) (range: 0–35) |
10.3 (7.6) (range: 0–35) |
7.2 (4.3) (range: 1–12) |
0.22** | |
| Time to cure (days) | 60 (range: 10–100) |
65 (range: 10–100) |
40.5 (range: 10–92) |
0.035*** | |
| Initial BCVA LogMAR (Snellen) | 0.83 (20/135) (range: 20/20-LP) |
0.89 (20/155) (range: 20/20-LP) |
0.65 (20/89) (range: 20/25-HM) |
0.38** | |
| Follow up BCVA LogMAR (Snellen) | 0.65 (20/89) (range: 20/20-LP) |
0.77 (20/118) (range: 20/20-LP) |
0.25 (20/36) (range:20/20–20/100) |
0.01** | |
| Penetrating Keratoplasty | 7 (14%) | 7 (18%) | 0 (0%) | 0.17* | |
| Follow up BCVA<20/200 | 9 (19%) | 9 (25%) | 0 (0%) | 0.09* | |
Treatment delay= time from the onset of symptoms to the initiation of antifungal agents.
Time to cure= duration of treatment necessary to eliminate evidence of clinically active infection.
*
Fisher’s exact test
**
t-test
***
Mann-Whitney test
†
Genus level (Fusarium sp)